For more than four decades, the Society for Immunotherapy of Cancer (SITC) has been guided by a singular mission: to improve outcomes for patients by advancing the science, development, and application of cancer immunotherapy. In a year marked by both complexity and innovation, the SITC family rose to the moment, advancing our strategic priorities with focus, resilience and purpose.
Building on the momentum of our strategic vision and the #SITCQuestfor100 initiative — our bold commitment to achieving 100 novel immuno-oncology agents approved by 2034 — SITC embraced new opportunities and elevated critical conversations across the field. Even amid a challenging external landscape, our leadership remained forward-looking and action-oriented.
Throughout 2025, SITC championed future-focused initiatives across diverse platforms. These included a biotech strategic meeting at the New York Stock Exchange examining opportunities to advance T-cell engagers, bispecifics, and in vivo CAR-T approaches; a summit dedicated to accelerating cell therapies for solid tumors; and the Leveraging Biomarkers Workshop, which underscored the essential role of biomarkers in advancing precision immuno-oncology. We also celebrated the full publication of The Next Wave of Immuno-Oncology: A Roadmap from the Society for Immunotherapy of Cancer (SITC) series in the Journal for ImmunoTherapy of Cancer (JITC), representing a significant scholarly contribution to the field.
Meaningful progress toward our broader goals was evident in 2025. Notably, the perioperative immuno-oncology space continued to gain momentum, with more than a third of FDA immuno-oncology approvals occurring in neoadjuvant and adjuvant settings – an encouraging indicator of both innovation and clinical impact.
SITC’s impact extends well beyond therapeutic development. Through our comprehensive educational offerings, workshops, and Annual Meeting, we reinforced our role as the premier forum for scientific exchange and community advancement. From virtual webinar series and in-depth scientific programming to immersive, in-person learning experiences, SITC continued to serve as the nexus of multidisciplinary collaboration and discovery.
At the same time, we amplified the voices of immunotherapy professionals worldwide, expanded opportunities for early-career scientists, and advocated for policies that support sustained research funding, expanded access to care and thoughtful regulatory pathways.
As we reflect on the achievements of 2025, we are reminded that SITC is more than the sum of its scientific advances. We are a resilient, global community united by a shared commitment to pushing the boundaries of what is possible for patients with cancer.
Thank you for your continued support, dedication, and partnership. Together we look forward to building on this year’s progress and charting an even brighter course in 2026.